KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Guardant Health (GH) over the last 9 years, with Q3 2025 value amounting to -$45.4 million.

  • Guardant Health's Net Cash Flow rose 8697.37% to -$45.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 9927.62%. This contributed to the annual value of -$502.2 million for FY2024, which is 15058.8% down from last year.
  • As of Q3 2025, Guardant Health's Net Cash Flow stood at -$45.4 million, which was up 8697.37% from -$69.3 million recorded in Q2 2025.
  • Guardant Health's Net Cash Flow's 5-year high stood at $675.3 million during Q4 2023, with a 5-year trough of -$356.9 million in Q2 2022.
  • Over the past 5 years, Guardant Health's median Net Cash Flow value was -$17.8 million (recorded in 2022), while the average stood at -$7.3 million.
  • As far as peak fluctuations go, Guardant Health's Net Cash Flow crashed by 61442.02% in 2022, and later soared by 536503.65% in 2025.
  • Guardant Health's Net Cash Flow (Quarter) stood at -$339.9 million in 2021, then soared by 94.76% to -$17.8 million in 2022, then surged by 3892.93% to $675.3 million in 2023, then crashed by 108.43% to -$56.9 million in 2024, then increased by 20.18% to -$45.4 million in 2025.
  • Its last three reported values are -$45.4 million in Q3 2025, -$69.3 million for Q2 2025, and $173.3 million during Q1 2025.